Emerging Company Profile
Through Aktis, MPM bets on radiotherapy for solid tumors
Emerging Company Profile: Aktis raises $72M A round to develop alpha-emitting radiotherapies with differentiated PK
Aktis Oncology raises a $72 million A round to develop α-emitting radiotherapies with differentiated PK.
Mar 18, 2021 | 11:43 PM GMT
Aktis believes the pharmacology of its solid tumor-targeting